ArticleKidney international reports2026
Reference Change Value Based AKI Criteria in Critically Ill Children.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Refining AKI Diagnosis: Is There a Return on the Investment?Kidney international reports · 2026Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Recently, a new criterion for acute kidney injury (AKI), the pediatric reference change value optimized for AKI in children (pROCK criterion), has been introduced, to account for the high analytical and biological variability observed with serum creatinine. However, there is limited information about this novel criterion. Methods: Consecutive children aged 1 month to 18 years admitted to the pediatric intensive care unit (PICU) of a tertiary care center from February 2023 to December 2024 were prospectively enrolled. Using the pROCK criterion, incidence of AKI within 7 days of PICU entry, and the diagnostic performance of this criteria was compared with other AKI criteria. Results: Of the 907 patients screened, 478 were found eligible and followed up with until discharge. The incidence of AKI as per pROCK, the Kidney Disease: Improving Global Outcomes (KDIGO), the Pediatric Risk, Injury, Failure, Loss of kidney function and End-stage renal disease (pRIFLE), and AKI Network (AKIN) criteria were 25.3%, 30.5%, 37.6%, and 30.5%, respectively. The incidence varied significantly based on the definition used to assume baseline creatinine, with the pROCK criteria identifying less false positives at low baseline creatinine. There was very good agreement between pROCK and KDIGO for identifying any AKI (kappa statistic [K] = 0.91) and No-AKI (K = 0.91), and good agreement for stage 3 AKI (K = 0.76). Whereas KDIGO offered the highest sensitivity (100%), pROCK had the highest specificity (96.2%). The pROCK criteria was an independent predictor of mortality. Conclusion: The pROCK criteria can effectively diagnose AKI, with the added advantage of specificity, thereby able to better identify "true AKI," especially in infants and young children with lower ranges of serum creatinine. Further refinement in the pROCK definition with incorporation of urine output criteria is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.